Previous 10 | Next 10 |
RegeneRx Issues 2022 Letter To Stockholders PR Newswire Update on Product Candidates, FDA Regulatory Strategy, Operations ROCKVILLE, Md. , Aug. 22, 2022 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "Regen...
RegeneRx Biopharmaceuticals ( OTCQB:RGRX ) on Monday said its U.S. JV partner and licensee had signed a letter of intent with a global contract research organization (CRO) to conduct two phase 3 trials in the U.S. and Europe for patients with neurotrophic keratitis (NK), a deg...
RegeneRx Partner Signs LOI with Global Ophthalmology CRO for Two Phase 3 Clinical Trials in Neurotrophic Keratitis PR Newswire ROCKVILLE, Md. , July 18, 2022 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx" or "Company"), a ...
RegeneRx Licensee to Expand Phase 3 Clinical Trial Program with RGN-259 PR Newswire ROCKVILLE, Md. , June 22, 2022 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx" or "Company"), a clinical-stage drug development company...
Tβ4 Shows Potential as a Combination Treatment for Diabetes-Induced Complications of the Cornea PR Newswire ROCKVILLE, Md. , May 4, 2022 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development com...
RegeneRx Provides Regulatory Update Regarding RGN-259 PR Newswire ROCKVILLE, Md. , March 2, 2022 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair a...
RegeneRx Consultant to Receive Prestigious Award for Contributions in Field of Health PR Newswire ROCKVILLE, Md. , Feb. 11, 2022 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on...
Researchers Confirm Thymosin Beta 4's Ability to Protect Eyes From Ethanol Injury PR Newswire ROCKVILLE, Md. , Jan. 25, 2022 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tis...
RegeneRx Publishes Regulatory Update on RGN-259 PR Newswire ROCKVILLE, Md. , Jan. 12, 2022 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protectio...
RegeneRx Joint Venture Will Hold Pre-BLA Meeting with FDA on February 28, 2022 Meeting Pursuant to BLA Application for Dry Eye Syndrome PR Newswire ROCKVILLE, Md. , Dec. 17, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneR...
News, Short Squeeze, Breakout and More Instantly...
Regenerx Biopharms Inc Company Name:
RGRX Stock Symbol:
OTCMKTS Market:
RegeneRx Effects Reverse Stock Split and Terminates SEC Reporting Obligations PR Newswire ROCKVILLE, Md. , Aug. 15, 2023 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("RegeneRx" or the "Company") , a clinical-stage drug development compa...
RegeneRx Receives Stockholder Approval for Reverse Stock Split PR Newswire ROCKVILLE, Md. , Aug. 7, 2023 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("RegeneRx" or the "Company") , a clinical-stage drug development company focused o...
RegeneRx To Extend Consent Solicitation Vote PR Newswire ROCKVILLE, Md. , Aug. 1, 2023 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("RegeneRx" or "Company"), a clinical-stage drug development company focused on tissue protection, repair, and...